NIMBEX LIQUID

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

CISATRACURIUM (CISATRACURIUM BESYLATE)

Disponibbli minn:

ABBVIE CORPORATION

Kodiċi ATC:

M03AC11

INN (Isem Internazzjonali):

CISATRACURIUM

Dożaġġ:

2MG

Għamla farmaċewtika:

LIQUID

Kompożizzjoni:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

10 ML(VIAL)

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

NEUROMUSCULAR BLOCKING AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0133260001; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2016-06-07

Karatteristiċi tal-prodott

_NIMBEX_
_®_
_ Product Monograph _
_Page 1 of 34 _
PRODUCT MONOGRAPH
PR
NIMBEX
®
cisatracurium besylate injection
solution for injection (2 mg/mL)
Non-depolarizing Skeletal Neuromuscular Blocking Agent
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR WITH
ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.
NOTE: NIMBEX
®
is a trademark of the Glaxo group of companies, AbbVie Corporation
licensed use.
_ _
Date of Preparation:
November 1, 2012
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Qc H4S 1Z1
Submission Control No: 158348
_NIMBEX_
_®_
_ Product Monograph _
_Page 2 of 34 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................12
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................26
SPECIAL HANDLING INSTRUCTIONS
.......................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................